Table 1.
Characteristics in all subjects, non-African Americans (AA) and AA
| Clinical characteristics | All subjects (Non-AA and AA) | Non-AA | AA |
|---|---|---|---|
| Number of subjects | 681 | 540 (79.3%) | 141 (20.7%) |
| Age (years) of recipient* | 50.2 ± 12.2 | 50.1 ± 12.2 | 46.9 ± 11.5 |
| Baseline weight (kg) of recipient* | 81.3 ± 18.7 | 81.1 ± 18.8 | 81.9 ± 17.9 |
| Gender of recipient (Male/Female) | 429 (63%)/252 (37%) | 338 (63%)/202 (37%) | 91 (65%)/50 (35%) |
| Number of transplants | |||
| 1 | 550 (81%) | 417 (77%) | 133 (94%) |
| ≥2 | 130 (19%) | 122 (23%) | 8 (6%) |
| Number transplanted at a steroid sparing centre | 205 (30%) | 197 (36.5%) | 8 (5.5%) |
| Living donor | 398 (59%) | 355 (66%) | 43 (31%) |
| Number of troughs | 11 823 | 9523 | 2300 |
| Mean tacrolimus daily dose in mg kg−1† | 0.08 ± 0.05 | 0.07 ± 0.05 | 0.09 ± 0.04 |
| Mean tacrolimus trough in ng ml−1† | 8.31 ± 3.48 | 8.66 ± 3.37 | 6.82 ± 3.51 |
| Number of patients with troughs <8 ng ml−1 | |||
| Week 1 | 413 (75%) | 307 (69%) | 106 (96%) |
| Week 2 | 331 (55%) | 228 (48%) | 103 (82%) |
| Calcium channel blocker use‡ | 5082 (43%) | 3915 (41%) | 1167 (51%) |
| CYP3A5 genotype | |||
| *1/*1 | 72 (11%) | 9 (2%) | 63 (45%) |
| *1/*3 | 129 (19%) | 70 (13%) | 59 (42%) |
| *3/*3 | 476 (70%) | 457 (85%) | 19 (13%) |
*
Reported age and baseline weight are those measured at the time of transplant and are mean ± SD
†
doses and troughs are over the 6-month study period and are mean ± SD
‡
calcium channel blocker use at the time of trough collection.